We would like to revise our current validation method for IHC antibodies.
Recently, we've had a lot discussion and no agreement on  "how to" and "to
what extent"  you need to validate antibodies which have already undergone
manufacturer's testing for specificity and sensitivity.   Should this be
treated in the same manner test are validated in the clinical laboratory?
Testing extensive  specimens and slides?  Or what is considered enough of
validation for patient testing.  I would appreciate it if anyone has a
policy/procedure that they would be willing to share.  We would like to
ensure that we are in compliance with the antibody validation process.

 

G.Deville, Histology Supv.

Delta Pathology, Mid-Louisiana

Box 30113, 211 Fourth Street

Alexandria, LA 71301

 

Work: (318)473-3943 / (318) 473-3180

Mobile: (318) 729-4203

Pager: (318) 427-5444

Email:   gdeville@deltapathology.com

 

 

_______________________________________________
Histonet mailing list
Histonet@lists.utsouthwestern.edu
http://lists.utsouthwestern.edu/mailman/listinfo/histonet